Study S001908

Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes: An Effectiveness-Implementation Hybrid Type 1 Randomized Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07797036
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 226
Start: 2027-09-01
Primary completion: 2030-09-01
Lead sponsor: University of Massachusetts, Worcester
Conditions: Gestational Diabetes Mellitus (GDM); Metabolic Syndrome
Interventions: DRUG:Semaglutide (Wegovy) weekly injection
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:U1111-1346-0976

Registered primary outcomes

Metabolic Syndrome [6 months after randomization]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.